News and commentary from the endocrinology world
Also in TTHealthWatch: menopause hormone therapy in the U.S.
Benefit in symptoms, functional outcomes remains to be seen for HU6
Limited benefit seen in patients with established cirrhosis, however
More noteworthy research from the EASD 2024 meeting
Saxenda group six times more likely to lose at least 5% of BMI